Ripasudil - Kowa Pharmaceutical

Drug Profile

Ripasudil - Kowa Pharmaceutical

Alternative Names: Glanatec; K-115; K-115-R; Ripasudil hydrocholoride hydrate

Latest Information Update: 14 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer Kowa Pharmaceutical
  • Class Azepines; Eye disorder therapies; Fluorine compounds; Isoquinolines; Small molecules; Sulfonamides
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase II Diabetic retinopathy

Most Recent Events

  • 31 Oct 2018 Kowa Pharmaceuticals completes the phase II ROCKHY trial in conjunctival hyperaemia in patients with Glaucoma and Ocular hypertension in Japan (Ophthalmic) (UMIN000019565)
  • 01 Apr 2017 Kowa initiates enrolment in a clinical trial for Glaucoma in Japan (JapicCTI-173562)
  • 28 Feb 2017 Phase-II development for Diabetic retinopathy is ongoing in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top